



**HAL**  
open science

## Activation of sarcolipin expression and altered calcium cycling in LMNA cardiomyopathy

Blanca Morales Rodriguez, Alejandro Domínguez-Rodríguez, Jean-Pierre Benitah, Florence Lefebvre, Thibaut Marais, Nathalie Mougenot, Philippe Beauverger, Gisèle Bonne, Véronique Briand, Ana-María Gómez, et al.

► **To cite this version:**

Blanca Morales Rodriguez, Alejandro Domínguez-Rodríguez, Jean-Pierre Benitah, Florence Lefebvre, Thibaut Marais, et al. Activation of sarcolipin expression and altered calcium cycling in LMNA cardiomyopathy. *Biochemistry and Biophysics Reports*, 2020, 22, pp.100767. 10.1016/j.bbrep.2020.100767 . hal-03269952

**HAL Id: hal-03269952**

<https://hal.sorbonne-universite.fr/hal-03269952v1>

Submitted on 24 Jun 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## Activation of sarcolipin expression and altered calcium cycling in *LMNA* cardiomyopathy



Blanca Morales Rodriguez<sup>a,b</sup>, Alejandro Domínguez-Rodríguez<sup>c</sup>, Jean-Pierre Benitah<sup>c</sup>, Florence Lefebvre<sup>c</sup>, Thibaut Marais<sup>a</sup>, Nathalie Mougenot<sup>d</sup>, Philippe Beauverger<sup>b</sup>, Gisèle Bonne<sup>a</sup>, Véronique Briand<sup>b</sup>, Ana-María Gómez<sup>c,1</sup>, Antoine Muchir<sup>a,\*,1</sup>

<sup>a</sup> Sorbonne Université, INSERM UMRS974, Paris, France

<sup>b</sup> Sanofi R&D, Chilly-Mazarin, France

<sup>c</sup> Inserm, Univ. Paris-Sud, Université Paris-Saclay, UMR-S 1180, "Signaling and Cardiovascular Pathophysiology", Châtenay-Malabry, France

<sup>d</sup> Sorbonne Université, INSERM, UMS28 Phénotypage du Petit animal, Paris, F-75013, France

### ARTICLE INFO

#### Keywords:

Sarcolipin  
Calcium handling  
Nuclear envelope  
*LMNA*  
Dilated cardiomyopathy

### ABSTRACT

Cardiomyopathy caused by A-type lamins gene (*LMNA*) mutations (*LMNA* cardiomyopathy) is associated with dysfunction of the heart, often leading to heart failure. *LMNA* cardiomyopathy is highly penetrant with bad prognosis with no specific therapy available. Searching for alternative ways to halt the progression of *LMNA* cardiomyopathy, we studied the role of calcium homeostasis in the evolution of this disease. We showed that sarcolipin, an inhibitor of the sarco/endoplasmic reticulum (SR) Ca<sup>2+</sup> ATPase (SERCA) was abnormally elevated in the ventricular cardiomyocytes of mutated mice compared with wild type mice, leading to an alteration of calcium handling. This occurs early in the progression of the disease, when the left ventricular function was not altered. We further demonstrated that down regulation of sarcolipin using adeno-associated virus (AAV) 9-mediated RNA interference delays cardiac dysfunction in mouse model of *LMNA* cardiomyopathy. These results showed a novel role for sarcolipin on calcium homeostasis in heart and open perspectives for future therapeutic interventions to *LMNA* cardiomyopathy.

### 1. Introduction

Mutations in the gene encoding A-type nuclear lamins (*LMNA*) cause dilated cardiomyopathy associated with conduction defects (*LMNA* cardiomyopathy) [1–3]. Lamins are intermediate filament proteins that polymerized to form the nuclear lamina, a fibrous meshwork underlining the inner nuclear membrane of most eukaryotic cells [4,5]. Despite optimization of conventional therapeutic strategies, terminal heart failure and post transplantation complications represent by far the most frequent cause of death. There are currently no effective treatments for *LMNA* cardiomyopathy. Thus, it is necessary to clarify its pathological mechanisms and to search for potential compounds to protect against *LMNA* cardiomyopathy.


To study the pathophysiology of *LMNA* cardiomyopathy and to test possible therapeutics, murine models of the disease [6] have enabled insights into pathological mechanisms [7–11]. All these mechanisms have been targeted with small-molecules in mice and showed some beneficial impact. However, these approaches were not curative.

Searching for alternative ways to slow down the cardiac disease progression, we here examined the involvement of calcium homeostasis in the *Lmna*<sup>H222P/H222P</sup> mouse model of the disease. Work from others converges to the conclusion that unhinged calcium (Ca<sup>2+</sup>) handling in the cardiomyocytes plays a central role in initiation and progression of dilated cardiomyopathy [12]. The regulation of Ca<sup>2+</sup> cycling is finely tuned by various proteins and regulatory processes, and is unhinged in cardiomyopathy. Therefore, the components of the Ca<sup>2+</sup> cycling apparatus have been widely studied, aiming to restore the Ca<sup>2+</sup> cycling process and ultimately improve the cardiac function. We here showed that sarcolipin (SLN), an inhibitor of the sarco/endoplasmic reticulum (SR) Ca<sup>2+</sup> ATPase (SERCA), was abnormally elevated in *LMNA* cardiomyopathy, leading to an alteration of calcium cycling. These results establish a novel role for sarcolipin on calcium homeostasis in cardiac muscle and provide a rationale for future therapeutic interventions in *LMNA* cardiomyopathy.

\* Corresponding author.

E-mail address: [a.muchir@institut-myologie.org](mailto:a.muchir@institut-myologie.org) (A. Muchir).

<sup>1</sup> Last joint authors: These authors contributed equally.



**Fig. 1. Activation of SLN in LMNA cardiomyopathy**

Representative immunoblot showing SLN expression in hearts from 6 months old male *Lmna*<sup>H222P/H222P</sup> and wild type (WT) mice. GAPDH was shown as loading control.

## 2. Results

### 2.1. Activation of cardiac SLN expression in *Lmna*<sup>H222P/H222P</sup> mice

To explore the role of calcium signaling in the development of LMNA cardiomyopathy, we studied a mouse model that display a *Lmna* mutation, the *Lmna*<sup>H222P/H222P</sup> mouse model [13]. *Lmna*<sup>H222P/H222P</sup> mice develop a progressive left ventricular dysfunction that recapitulates human LMNA cardiomyopathy (Fig. S1) [13]. *Lmna*<sup>p.H222P</sup> mutation was found associated with dilated cardiomyopathy in human [14]. We previously studied expression of mRNAs isolated from hearts from young *Lmna*<sup>H222P/H222P</sup> mice, at 10 weeks of age [7]. This analysis highlighted activation of the expression of *Sln* gene, encoding sarcoplipin (SLN), in *Lmna*<sup>H222P/H222P</sup> mice compared with wild type mice [7]. The up-regulation of SLN was also observed at 6 months of age in cardiac ventricles from *Lmna*<sup>H222P/H222P</sup> mice (Fig. 1), when the left ventricular function was altered. SLN activation was also observed at a younger age, when no left ventricular dysfunction was reported (Fig. 2).


Given that several proteins tightly regulate defective  $[Ca^{2+}]_i$  cycling, we investigated whether the expression of calcium handling proteins was altered in LMNA cardiomyopathy. We found that expression of SERCA2a (Fig. 2, Fig. S2A) and NCX (Fig. 2, Fig. S2A) were not affected in hearts of 6-month old *Lmna*<sup>H222P/H222P</sup> mice. We also reported that expression of these proteins was not different from wild type mice at 3 months of age, when the left ventricular function was normal (Fig. 2). The expression of phospholamban (PLB), a regulator of SERCA2a, was decreased in the hearts from the *Lmna*<sup>H222P/H222P</sup> mice (Fig. 3A, Fig. S2B). This was ensuing an increased relative phosphorylation of PLB on residues Ser16 and Thr17 in the hearts from *Lmna*<sup>H222P/H222P</sup> mice (Fig. 3B, Fig. S2B). We then used a cellular model to assess the balance between SLN and PLB expression. We generated HL-1 cells stably expressing FLAG-tagged SLN (Fig. 3C). PLB expression was increased in these cells relative to HL-1 (Fig. 3D). These results demonstrated a correlation between enhanced SLN expression and

decreased PLB expression in cardiac cells.

### 2.2. Altered calcium homeostasis in *Lmna*<sup>H222P/H222P</sup> mice caused by SLN up-regulation


Given that SLN is a regulator of cardiac calcium handling through its inhibitory role on SERCA2a, we next hypothesized that over-expression of SLN in *Lmna*<sup>H222P/H222P</sup> mice could affect calcium homeostasis before detectable cardiac dysfunction.  $[Ca^{2+}]_i$  transients were elicited by electrical stimulation in ventricular cardiomyocytes from 3-month old *Lmna*<sup>H222P/H222P</sup> mice. Given that A-type lamins are important in nuclear pores organization [15], through which  $Ca^{2+}$  is diffused into the nucleus, and that nuclear  $Ca^{2+}$  is involved in gene transcription activation, we therefore set-up the scanning line through the nucleus to simultaneously record cytosolic  $[Ca^{2+}]_i$  and nuclear  $[Ca^{2+}]_n$  transients (Fig. 4A). The peak  $[Ca^{2+}]_i$  transient (F/F<sub>0</sub>) was not significantly different between ventricular cardiomyocytes from *Lmna*<sup>H222P/H222P</sup> mice and wild type mice (Fig. 4B), which is consistent with the normal heart contractile function reported in *Lmna*<sup>H222P/H222P</sup> mice at early stage (3 months) (Fig. S1). We showed that kinetics of the  $[Ca^{2+}]_i$  transients were slowed in ventricular cardiomyocytes from *Lmna*<sup>H222P/H222P</sup> mice compared with cardiomyocytes from wild type mice. The  $[Ca^{2+}]_i$  transient decay time was significantly prolonged in myocytes from *Lmna*<sup>H222P/H222P</sup> mice compared with those from wild type mice, suggesting slower  $Ca^{2+}$  uptake by the SERCA2a pump. However, the nuclear  $[Ca^{2+}]_n$  transient was not significantly different between the two types of cardiomyocytes (Fig. 4B). This suggests that sarcoplasmic reticulum (SR) calcium uptake was slowed in *Lmna*<sup>H222P/H222P</sup> mice, although the amplitude of the  $[Ca^{2+}]_i$  transient was maintained at this age. Because  $[Ca^{2+}]_i$  transients are triggered by the action potentials (AP), we next investigated whether AP characteristics were altered in cardiomyocytes from *Lmna*<sup>H222P/H222P</sup> mice. We showed that the zero current potential (Fig. 5A and B), amplitude (Fig. 5B), maximum dV/dt (Fig. 5C) and duration (Fig. 5D) were not significantly different between cardiomyocytes from *Lmna*<sup>H222P/H222P</sup> mice and wild type mice. The densities of outward potassium currents (transient outward  $I_{to}$ , ultrarapid  $I_{Kur}$  and sustained  $I_{ss}$ ) involved in AP repolarization phase were also similar between cardiomyocytes from *Lmna*<sup>H222P/H222P</sup> mice and wild type mice (Fig. 6A, B, 6C) despite the fact that the total membrane surface, measured as membrane capacitance, was smaller in cardiomyocytes isolated from *Lmna*<sup>H222P/H222P</sup> mice (Fig. 6D). Altogether, these data suggest that the alterations in  $[Ca^{2+}]_i$  handling were independent on an alteration of the electrophysiological characteristics of the cardiomyocyte from *Lmna*<sup>H222P/H222P</sup> mice.

The amount of  $Ca^{2+}$  released in each twitch depends on the amount of  $Ca^{2+}$  stored in the sarcoplasmic reticulum (SR), which can be estimated by rapid caffeine application (Fig. 4C). Fig. 4D showed no



**Fig. 2. Expression of Serca2a and NCX in LMNA cardiomyopathy**

Representative immunoblots showing SLN, Serca2a and NCX expression in ventricles from 3 and 6 months old male *Lmna*<sup>H222P/H222P</sup> and wild type (WT) mice. GAPDH was shown as loading control.




**Fig. 3. Expression of protein involved in calcium handling in LMNA cardiomyopathy.**

(A) Representative immunoblots showing total PLB, phosphorylated PLB(Ser<sub>16</sub>) and phosphorylated PLB(Thr<sub>17</sub>) expressions in hearts from 6 months-old male *Lmna*<sup>H222P/H222P</sup> and wild type (WT) mice. GAPDH was shown as loading control.

(B) Schematic representation of the construct.

(C) Representative immunoblots showing total PLB and phosphorylated PLB(Ser<sub>16</sub>) expressions in HL-1 cells stably expressing FLAG epitope-tagged SLN (FLAG-SLN).

(D) Micrographs showing PLB labeling in HL-1 cells (empty) and HL-1 cells stably expressing FLAG epitope-tagged SLN (FLAG-SLN). Nuclei are counter-stained with 4',6-diamidino-2-phenylindole (dapi).



**Fig. 4.** Alteration of calcium cycling in *LMNA* cardiomyopathy.

(A) Line-scan images during field stimulation at 2 Hz of representative isolated cardiomyocytes from 3 months-old wild type (WT) and *Lmna*<sup>H222P/H222P</sup> mice. Below each image, there are represented the fluorescence traces in black for the cytosolic  $[Ca^{2+}]_i$  transient, and in gray for the  $Ca^{2+}$  transient inside the nucleus in the WT cell. The same for the *Lmna*<sup>H222P/H222P</sup> in red (cytosolic) and in dark red (nuclear).

(B) Graph showing values of peak calcium transients ( $F/F_0$ ), peak nuclear calcium transients ( $F/F_0$ ), time to peak and decay time constant of steady-state  $Ca^{2+}$  transients from isolated cardiomyocytes from 3 months-old wild type (WT) and *Lmna*<sup>H222P/H222P</sup> mice. The number of cardiomyocytes is indicated. (t-test).

(C) Line-scan images of caffeine-evoked intracellular  $Ca^{2+}$  transients after field stimulation at 2 Hz of representative isolated cardiomyocytes from 3 months-old wild type (WT) and *Lmna*<sup>H222P/H222P</sup> mice obtained by the application of 10 mmol/L caffeine.


(D) Graph showing values of maximum amplitude of caffeine-induced SR  $Ca^{2+}$  release, indicative of SR  $Ca^{2+}$  load ( $F/F_0$ ) and decay time constant of caffeine-induced SR  $Ca^{2+}$  release, indicative of cytosolic  $Ca^{2+}$  extrusion  $Ca^{2+}$  from isolated cardiomyocytes from 3 months-old wild type (WT) and *Lmna*<sup>H222P/H222P</sup> mice. The number of cardiomyocytes is indicated. (t-test).

significant difference in SR  $Ca^{2+}$  load (Peak  $[Ca^{2+}]_i$  transient ( $F/F_0$ )), which is consistent with the normal  $[Ca^{2+}]_i$  transient amplitude. Moreover, the decay time constant during caffeine perfusion between cardiomyocytes isolated from *Lmna*<sup>H222P/H222P</sup> mice and wild type mice was also similar, showing no changes in  $Ca^{2+}$  extrusion though the NCX in myocytes from the mutated mice, and thus indicating that the slowing on the decay phase of the electrically evoked  $[Ca^{2+}]_i$  transient (Fig. 4B) is due to SERCA slowing.

### 2.3. SLN up-regulation induces cardiac dysfunction

We next tested the hypothesis that SLN overexpression influences left ventricular function *in vivo*. We injected adeno-associated virus (AAV) vector expressing GFP-tagged shRNA against SLN (shSLN) in 1 month-old *Lmna*<sup>H222P/H222P</sup> mice. Following four months of treatment, the mice were analyzed by echocardiography and sacrificed for biochemical and histological studies. There was less alteration of

myocardial fibrosis in hearts from *Lmna*<sup>H222P/H222P</sup> mice infected with GFP-tagged shSLN relative to mice injected with PBS (Fig. 7A and B). Compared with non-transduced *Lmna*<sup>H222P/H222P</sup> mice, for which the fractional shortening decreased overtime, fractional shortening in shSLN-transduced *Lmna*<sup>H222P/H222P</sup> mice did not change at 4 months of age (Fig. 7C, Table 1). This effect on the left ventricular function was transient as shSLN-transduced *Lmna*<sup>H222P/H222P</sup> mice showed an altered cardiac function no significantly different to non-transduced *Lmna*<sup>H222P/H222P</sup> mice at 5 months of age (Fig. 7C, Table 1). The inhibition of SLN expression in *Lmna*<sup>H222P/H222P</sup> mice (Fig. 7D) was followed by an increased cardiac expression of PLB (Fig. 7E, Fig. S3). This was followed by a decreased phosphorylation of PLB on residues Ser16 and Thr17 reported to total PLB expression in the hearts from shSLN-transduced *Lmna*<sup>H222P/H222P</sup> mice compared with non-transduced mice. (Fig. 7E, Fig. S3). These results showed that partially inhibiting SLN *in vivo* is efficient to delay the left-ventricular function in a mouse model of *LMNA* cardiomyopathy.



**Fig. 5.** Electrophysiological characteristics in cardiomyocytes isolated from *Lmna*<sup>H222P/H222P</sup> mice (A) Examples of action potentials (AP) recorded in wild type (WT) (black trace) and *Lmna*<sup>H222P/H222P</sup> (red trace) cells. Membrane resting potential measured as the Zero current potential (left) and AP amplitudes (right) (B), maximum AP upstroke velocity (measured as dV/dt) (C), and AP duration (APD) at 20, 50, and 90% of repolarization. (D). The number of cardiomyocytes is indicated. Data are represented as the mean  $\pm$  standard deviation of individuals. (t-test). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

### 3. Discussion

We showed in this study that expression of cardiac SLN, an inhibitor of the sarco/endoplasmic reticulum (SR) Ca<sup>2+</sup> ATPase (SERCA), was up regulated in ventricles from *Lmna*<sup>H222P/H222P</sup> mice and [Ca<sup>2+</sup>]<sub>i</sub> transients were slowed down early before the development of cardiomyopathy symptoms. We therefore hypothesized that chronic SERCA2a inhibition contributes to cardiac muscle pathogenesis in *LMNA* cardiomyopathy. We tested our hypothesis using shRNA approach in *Lmna*<sup>H222P/H222P</sup> mice, and found that reduction in SLN expression was sufficient to delay left ventricular dysfunction. These results suggest a novel mechanism in the regulation of pathophysiology in *LMNA* cardiomyopathy.


We have reported for the first time an alteration in the Ca<sup>2+</sup> handling in cardiomyocytes from *Lmna*<sup>H222P/H222P</sup> mice. The prolongation of the [Ca<sup>2+</sup>]<sub>i</sub> transient duration can be explained either by impairment in Ca<sup>2+</sup> recapture by the SR through SERCA2a or by a decrease in Ca<sup>2+</sup> extrusion through NCX1 [16,17]. Our data suggest that only the recapture by the SR mechanisms was altered in cardiomyocytes from *Lmna*<sup>H222P/H222P</sup> mice. A decreased SERCA2a function is commonly observed in models of heart failure, with both reduced and preserved ejection fraction (HFpEF) [18,19]. While in overt heart failure SR Ca<sup>2+</sup> content and [Ca<sup>2+</sup>]<sub>i</sub> transient amplitudes are depressed, accounting for reduced contractile function, in HFpEF those parameters are normal as in *Lmna*<sup>H222P/H222P</sup> mice. The preservation in SR Ca<sup>2+</sup> load in *Lmna*<sup>H222P/H222P</sup> mice suggests that SERCA2a can keep pumping enough Ca<sup>2+</sup> to maintain cell contraction, notwithstanding an alteration of its function. Thus the decreased Ca<sup>2+</sup> re-uptake in *Lmna*<sup>H222P/H222P</sup> mice is still not enough to decrease SR Ca<sup>2+</sup> at normal heart rate, so contractile function can be sustained for a while, but the left ventricular function will ultimately decline overtime (Fig. S1).

SERCA2a function in cardiac muscle is regulated by SR membrane proteins, PLB and SLN, both inhibiting SERCA function [20,21]. Here,

we showed that the abnormal activation of SLN in cardiac cells and in the heart of a murine model of *LMNA* cardiomyopathy was followed by a decreased PLB expression. Our results are divergent from work from others [22], as we showed that SLN overexpression induced changes in the expression of PLB. Because a number of conditions may affect PLB expression including sample preparation, disease state, and model, these findings may require additional experimentation. Our findings suggest that the stoichiometry between PLB and SLN is important for the regulation SERCA2a in cardiac pathophysiology, according to work from others [23]. It has been previously described that overexpression of SLN is slowing calcium reuptake by the SR, demonstrating that SLN inhibits SERCA2a, which leads to decreased rates of calcium uptake and decreased contractility [21,24]. Nevertheless, our data show that the decrease in PLB expression was not sufficient to maintain the physiological Ca<sup>2+</sup> re-uptake in cardiomyocytes from *Lmna*<sup>H222P/H222P</sup> mice, suggesting that the slowed SERCA2a function was related to the activation of SLN expression.

Ca<sup>2+</sup> handling alteration may be involved in cardiac dysfunction that appears progressively in *Lmna*<sup>H222P/H222P</sup> mice. [Ca<sup>2+</sup>]<sub>i</sub> plays an important role in the progression of cardiac disease by activating the so-called excitation-transcription coupling [25]. This mechanism is dependent on calcineurin activation by Ca<sup>2+</sup> in the cytosol and/or Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII) in the nucleus [26,27]. The impeded [Ca<sup>2+</sup>]<sub>i</sub> transient duration could activate calcineurin signalling, leading to *LMNA* cardiomyopathy. Supporting this hypothesis, it has been shown that SLN overexpression increases calcineurin activity [28] while SLN deletion tends to inhibit calcineurin activity [29,30].

Regulation of SERCA2a by targeting SLN expression in *LMNA* cardiomyopathy could be an interesting approach to normalize Ca<sup>2+</sup> homeostasis. Consistent with our data, recent work in Duchenne muscular dystrophy (DMD), a severe form of muscular dystrophy with cardiomyopathy [31], reported a cardiac SLN overexpression [32]. In



**Fig. 6.** Potassium currents density in cardiomyocytes isolated from *Lmna*<sup>H222P/H222P</sup> mice.


(A) Transient outward potassium current ( $I_{to}$ ) recorded in 27 cells from wild type (WT) (black circles) and 22 *Lmna*<sup>H222P/H222P</sup> cells (red circles) from 3 mice for each genotype. Current amplitude (pA) was normalized by the membrane capacitance (pF), which is an indirect measurement of cell surface.  
 (B) Transient ultra-rapid potassium current ( $I_{Kur}$ ) recorded in 18 wild type (WT) and 15 *Lmna*<sup>H222P/H222P</sup> cells from 3 mice for each genotype. Current amplitude (pA) was normalized by the membrane capacitance (pF), which is an indirect measurement of cell surface.  
 (C) Transient sustained potassium current ( $I_{ss}$ ) recorded in 20 wild type (WT) and 15 *Lmna*<sup>H222P/H222P</sup> cells from 3 mice for each genotype. Current amplitude (pA) was normalized by the membrane capacitance (pF), which is an indirect measurement of cell surface.  
 (D) Membrane capacitance. The number of cardiomyocytes is indicated. (*t*-test).

In this study, Voit et al. described a decreased SERCA2a function activity in the heart of a DMD mouse model, the *mdx* mice [32]. Furthermore, these authors and others showed that the reduction in SLN expression in *mdx* mice was sufficient to improve the SERCA function in heart [32] and in skeletal muscle [33]. These data, together with the present study, suggest that SLN could be a target to improve cardiac function in inherited cardiomyopathies. However, the impact of reduction in SLN expression on SERCA2a function remains to be tested in *LMNA* cardiomyopathy. The partial effect on cardiac function by reduction in SLN expression could reflect the fact that other molecular and cellular defects reported in *LMNA* cardiomyopathy [7–11,34,35] were not targeted by our approach and could still hamper the cardiac function. Therefore, our work encourages further approaches to mechanically assess the role played by SLN on calcium handling.

Our findings suggest that drugs that could correct unhinged calcium handling would ameliorate *LMNA* cardiomyopathy. In this regard, we previously showed that the use of pyridazinone derivative  $Ca^{2+}$  sensitizing agent SCH00013 was beneficial on cardiac function in *Lmna*<sup>H222P/H222P</sup> mice, inducing increased life expectancy and decreased fibrosis [36]. We therefore brought further evidence that the role of calcium handling is of importance in the development of *LMNA*

cardiomyopathy. Moreover, SLN overexpression has been detected in humans with different cardiac pathologies contributing to the contractile dysfunction [37,38]. Therefore, we could speculate that the regulation of SLN may not be specific to *LMNA* cardiomyopathy but occurs in several cardiomyopathies.

In conclusion, we showed for the first time that the calcium handling is disturbed in *LMNA* cardiomyopathy before overt signs of cardiac dysfunction, which can be, at least partially due to SLN overexpression. This work opens novel perspectives for further therapeutic interventions. How mutated A-type lamins regulate SLN expression remains an unanswered question. A-type lamins is known to have regulatory roles on gene transcription [39–41], through interaction with gene promoters [42]. *LMNA* mutants could therefore lead to alteration of A-type lamins–chromatin associations and transcriptional defects [43], which could have downstream effects on cardiac function [44]. Whether mutated A-type lamins alter *SLN* promoter is unclear and would require further investigation.



**Fig. 7.** Inhibition of SLN expression delays cardiac dysfunction in a mouse model of *LMNA* cardiomyopathy.

(A) Representative Sirius Red staining and 3D visualization of fibrosis (Fiji software) of cross sections of hearts from PBS-treated  $Lmna^{H222P/H222P}$  and shSLN-treated  $Lmna^{H222P/H222P}$  mice. Cross sections of hearts from wild type (WT) mice were shown as controls.

(B) Graph showing fibrosis quantification from PBS-treated  $Lmna^{H222P/H222P}$  and shSLN-treated  $Lmna^{H222P/H222P}$  mice.

(C) Fractional shortening evolution from 3 months to 5 months from PBS-treated  $Lmna^{H222P/H222P}$  (n = 5) and shSLN-treated  $Lmna^{H222P/H222P}$  mice (n = 5). Data are represented as the mean  $\pm$  standard deviation of individuals. \*\* $P \leq 0.01$  between PBS-injected  $Lmna^{H222P/H222P}$  mice and wild type mice at each time point (ANOVA).

(D) Representative immunoblot SLN expression in heart from PBS-treated  $Lmna^{H222P/H222P}$  and shSLN-treated  $Lmna^{H222P/H222P}$  mice. GAPDH was shown as loading control.

(E) Representative immunoblot showing GFP, total PLB, phosphorylated PLB(Ser<sub>16</sub>) and phosphorylated PLB(Thr<sub>17</sub>) expressions in heart from PBS-treated  $Lmna^{H222P/H222P}$  and shSLN-treated  $Lmna^{H222P/H222P}$  mice. GAPDH was shown as loading control.

## 4. Methods

### 4.1. Animals

All animal experiments were approved by the French Ministry of Health at the Center for Research in Myology for the Care and Use of Experimental Animals (approval number #5556). Experiments were performed according to guidelines from directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.  $Lmna^{H222P/H222P}$  mice were fed standard chow and housed in a disease-free barrier facility with 12h/12h light/dark cycles. Mice were sacrificed with cervical dislocation.

### 4.2. Isolation of mouse cardiomyocytes

Wild type and  $Lmna^{H222P/H222P}$  mice were anesthetized with intraperitoneal injection of sodium pentobarbital (50 mg/kg). Ventricular cardiomyocytes were isolated as described earlier [45].

### 4.3. Confocal microscopy and electrophysiological measurements

Isolated ventricular cardiomyocytes were loaded with the fluorescence  $Ca^{2+}$  dye Fluo-3 AM and viewed with a Leica microscopy in the line scan mode as earlier described<sup>45</sup>.  $[Ca^{2+}]_i$  transients were elicited by field stimulation through two Pt electrodes at 2 Hz.  $Ca^{2+}$  sparks were recorded in quiescent myocytes and SR  $Ca^{2+}$  load estimated by rapid caffeine (10 mM) application right after electrical stimulation at 2 Hz. Images were analyzed by home-made routines in IDL (Harris Aerospace). The patch-clamp method in the configuration of whole cell was used to record action potentials in the current clamp configuration and potassium currents in the voltage-clamp configuration. Protocols and solutions were previously described [45].

### 4.4. Protein extraction and western blot analysis

Total proteins were isolated from heart tissue or cultured cell in extraction buffer (Cell Signaling). The heart samples were extracted with Lysis-D tube using Fast-Prep (3 pulses of 45 s), the cells samples



**Table 1**  
Echocardiographic parameters for male *Lmna*<sup>H222P/H222P</sup> mice at 3, 4 and 5 months of age after AAV9-shSLN injection.

Genotype	Treatment	n	Heart rate (beats/min)	LVEDD (mm)	LVESD (mm)	FS (%)
<b>3 months</b>						
<i>Lmna</i> WT	none	5	317.2 ± 24.3	3.6 ± 0.1	1.9 ± 0.1	47.3 ± 0.4
<i>Lmna</i> H222P	PBS	5	346.2 ± 36.3	3.6 ± 0.1	2.0 ± 0.1 #	43.5 ± 1.3 ##
<i>Lmna</i> H222P	shSLN	5	286.0 ± 31.8	4.0 ± 0.3*	2.3 ± 0.3	41.0 ± 4.8
Genotype	Treatment	n	Heart rate (beats/min)	LVEDD (mm)	LVESD (mm)	FS (%)
<b>4 months</b>						
<i>Lmna</i> WT	none	5	367.0 ± 26.2	3.4 ± 0.2	1.8 ± 0.1	48.2 ± 0.7
<i>Lmna</i> H222P	PBS	5	326.4 ± 34.3 #	3.8 ± 0.2###	2.6 ± 0.2 ###	32.3 ± 4.6 ##
<i>Lmna</i> H222P	shSLN	5	331.4 ± 9.9	3.8 ± 0.1	2.2 ± 0.1 *	40.5 ± 2.5 **
Genotype	Treatment	n	Heart rate (beats/min)	LVEDD (mm)	LVESD (mm)	FS (%)
<b>5 months</b>						
<i>Lmna</i> WT	none	5	352.0 ± 32.8	3.7 ± 0.1	2.0 ± 0.1	45.5 ± 1.6
<i>Lmna</i> H222P	PBS	5	348.2 ± 25.2	3.9 ± 0.2	2.6 ± 0.2 ##	33.9 ± 4.0 ##
<i>Lmna</i> H222P	shSLN	5	313.8 ± 45.8	4.2 ± 0.5	3.0 ± 0.5	29.6 ± 5.2

Mean ± standard deviation are presented for each parameter, timepoint, genotype and treatment.

#P < 0.05, ##P < 0.01, ###P < 0.001 between PBS-injected *Lmna*<sup>H222P/H222P</sup> mice and wild type mice.

\*P < 0.05, \*\*P < 0.01 between PBS and shSLN-injected *Lmna*<sup>H222P/H222P</sup> mice. (ANOVA).

were sonicated (5 pulses of 10 s at 30% amplitude) to allow dissociation of protein from chromatin and solubilization. Sample protein content was determined by the BiCinchoninic Acid Assay protein assay (Thermo Fisher Scientific). Extracts were analyzed by SDS-PAGE using Tris-glycine gels (Life Technologies) and transferred onto nitrocellulose 0.2 µm membrane (novex, Life Technologies). Membranes were blocked 1 h with 5% bovine serum albumin (BSA) in phosphate buffer saline containing 1% Tween 20 (PBS-T). Subsequently to blocking, the membranes were incubated with primary antibodies overnight at 4 °C. After TBS-T washes membranes were incubated with anti-chicken, anti-mouse or anti-rabbit antibodies for 1 h at room temperature and washed again with TBS-T. The signal was then revealed using Immobilon Western Chemiluminescent HorseRadish Peroxidase (HRP) Substrate (Millipore) on a G-Box system with GeneSnap software (Ozyme).

#### 4.5. Cell culture and reagents

HL-1 (Merck Millipore) were maintained at 37 °C with 5% CO<sub>2</sub>. HL-1 cells were culture in Claycomb Medium (Sigma-Aldrich) supplemented with 10% FBS (Invitrogen), 1% penicillin/streptomycin (Invitrogen), norepinephrine 0.1 mM (Sigma-Aldrich) in 30 mM ascorbic acid (Sigma-Aldrich) and L-glutamine 2 mM with the required gelatin/fibronectin coating. HL-1-SLN cells were created using lentiviral vector EF1.GOI (Sarcolipin Tag Flag) (Vectalys). MOI: 100, cells were incubated with the lentiviral vector for 24h followed by a 2-day incubation with normal medium and a 3–5 days puromycin selection.

#### 4.6. Antibodies

Primary antibodies used were: SLN for Western blot (Merck Millipore, #ABT13), SERCA2a (Abcam, #ab2861), PLB (Cell Signaling, #14562), phospho-PLB(Ser16) (Santa Cruz, SC-12963-R), phospho-PLB (Thr17) (Santa Cruz, SC-17024-R), FLAG (Sigma, F3165), GAPDH (Santa Cruz, sc-47724). Secondary antibodies for immunoblotting were HRP-conjugated donkey anti-chicken (Invitrogen), rabbit anti-mouse or goat anti-rabbit IgG (Jackson ImmunoResearch). Secondary antibodies for immunofluorescence were Alexa Fluor 488 conjugated goat anti-rabbit IgG, Alexa Fluor 568-conjugated goat anti-mouse IgG, Alexa Fluor 488-conjugated goat anti-chicken IgG (Life Technologies).

#### 4.7. Immunofluorescence microscopy

HL-1 cells were grown in coated (gelatin/fibronectin) coverslips. Cells were fixed (10 min, 4% paraformaldehyde in PBS at room temperature), permeabilized (8 min, 0.5% Triton X-100 in PBS), blocked (1h, in PBS with 0.3% triton X-100 and 5% BSA) and incubated with primary antibodies (1h30 at RT, in PBS with 1% triton X-100 and 1% BSA). The section were then washed in PBS (3 times 5 min) and incubated with secondary antibodies (1 h at RT, in PBS with 1% triton X-100 and 1% BSA) and washed (3 times 5 min).

#### 4.8. Histology

Hearts were fixed in 4% formaldehyde for 48h, embedded in paraffin, sectioned at 5 mm and stained with Sirius red and hematoxylin eosin. Representative stained sections were photographed using a Microphot SA (Nikon) light microscope attached to a Spot RT Slide camera (Diagnostic Instruments). Images were processed using Adobe Photoshop CS (Adobe Systems) [35].

#### 4.9. Echocardiography

Mice were anesthetized with 0.75% isoflurane in O<sub>2</sub> and placed in a heating pad. Transthoracic echocardiography was performed using a Vivid 7 Dimension/Vivid7 PRO ultrasound with an 11 MHz transducer applied to the chest wall [34,35].

#### 4.10. Construction and injection of AAV encoding sh-SLN

AAV9-GFP-U6-mSLN-shRNA (VectorBiolabs) recombinant AAV viruses were produced through co-transfecting HEK293 cells with (i) the AAV plasmid encoding sh-SLN, (ii) the adenovirus helper plasmid and (iii) the AAV packaging plasmid encoding the rep2 and cap. Two days after transfections, cells were harvested, and AAV vectors were purified through CsCl-gradient ultra-centrifugation. Vector titers (GC/ml - genome copies/ml) were determined by real-time PCR. One month-old mice were injected with AAV9-GFP-U6-mSLN-shRNA into the retro-orbital vein (5 × 10<sup>13</sup> viral genomes/kg in 100 µl).

#### 4.11. Statistics

Graphics were performed using GraphPad Prism 8 software. For

both *in vivo* pharmacology studies and each parameter, statistical analyses were performed to evaluate the pathology effect by comparing *Lmna*<sup>H222P/H222P</sup> mice versus wild type mice, then for the study from 3 to 5 months to evaluate the effect of treatment on *Lmna*<sup>H222P/H222P</sup> mice by comparing the AAV9-shSLN treatment group to the PBS treatment group. For each objective an analysis of variance (ANOVA) with interaction was performed on factors “Time” (repeated) and “Group” or “Treatment” depending on the case. The variances heterogeneity was taken into account if necessary. Appropriate post-hoc analysis was then performed. The significance level is taken to 5%, except for the interaction test for which the significance level is taken to 10%. For *in vitro* pharmacology studies and each parameter, statistical analyses were performed to evaluate the pathology effect by comparing *Lmna*<sup>H222P/H222P</sup> mice versus wild type mice. A student *t*-test for mRNA expression and Cm parameter, a mixed effect model for calcium cycling, action potentials and sparks characteristics were carried out. The variances heterogeneity was taken into account if necessary. A log-transformation was performed for parameters peak calcium transients (peak F/F0), peak nuclear calcium transients (peak F/F0 (nucleus)), time to peak, decay time constant of caffeine-induced SR Ca<sup>2+</sup> release, APD20%, APD50% and APD90%, sparks frequency, sparks peak F/F0 and D<sub>50</sub>. A rank-transformation was performed for parameters zero current potential and amplitude. Due to convergence issue of the mixed effect model on the raw data for Cm parameter, the mean of Cm by animal was analyzed. The significance level was taken to 5%. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) on Windows 7 PC.

## Funding

This work was supported by the Association Française contre les Myopathies, the Institut National de la Santé et de la Recherche Médicale, Sorbonne Université and ANR (ANR-13-BSV1-0023-01 to A-M.G. and ANR-15-CE14-005 to JPB). B.M.R. was funded by Sanofi through a CIFRE PhD grant.

## Author contributions

Conceptualization, A.M.; Investigation, B.M.R., A.D-R., J-P.B., T.M., N.M., A-M.G. and A.M.; Sample preparation, B.M.R. and F.L.; Writing – Original Draft, A.M. and A-M.G.; Writing – Review & Editing, B.M.R., V.B., G.B., A-M.G. and A.M.; Funding Acquisition, A-M.G. and A.M.; Supervision, P.B., G.B., V.B. and A.M.

## Declaration of competing interest

B.M.R., V.B. and P.B. are employed by Sanofi, a global pharmaceutical company focused on human health.

A.D-R., J-P.B., F.L., T.M., N.M., G.B., A-M.G. and A.M. do not have any conflict of interest.

## Acknowledgements

We thank Dorothée Tamarelle for help with statistical analysis.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bbrep.2020.100767>.

## References

- [1] G. Bonne, M.R. Di Barletta, S. Varnous, et al., Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy, *Nat. Genet.* 21 (1999) 285–288.
- [2] D. Fatkin, C. MacRae, T. Sasaki, et al., Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease, *N. Engl. J. Med.* 341 (1999) 1715–1724.
- [3] S. Kumar, S.H. Baldinger, E. Gandjbakhch, et al., Long-term arrhythmic and non-arrhythmic outcomes of lamin A/C mutation carriers, *J. Am. Coll. Cardiol.* 68 (2016) 2299–2307.
- [4] L. Gerace, A. Blum, G. Blobel, Immunocytochemical localization of the major polypeptides of the nuclear pore complex-lamina fraction. Interphase and mitotic distribution, *J. Cell Biol.* 79 (1978) 546–566.
- [5] U. Aebi, J. Cohn, L. Buhle, L. Gerace, The nuclear lamina is a meshwork of intermediate-type filaments, *Nature* 323 (1986) 560–564.
- [6] M. Chatzifrangkeskou, G. Bonne, A. Muchir, Nuclear envelope and striated muscle diseases, *Curr. Opin. Cell Biol.* 32 (2015) 1–6.
- [7] A. Muchir, P. Pavlidis, V. Decostre, A.J. Herron, T. Arimura, et al., Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy, *J. Clin. Invest.* 117 (2007) 1282–1293.
- [8] A. Muchir, W. Wu, J.C. Choi, S. Iwata, J.P. Morrow, et al., Abnormal p38 $\alpha$  mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation, *Hum. Mol. Genet.* 21 (2012) 4325–4333.
- [9] J.C. Choi, A. Muchir, W. Wu, S. Iwata, S. Homma, et al., Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation, *Sci. Transl. Med.* 4 (2012) 144ra102.
- [10] M. Chatzifrangkeskou, C. Le Dour, W. Wu, J.P. Morrow, L.C. Joseph, et al., ERK1/2 directly acts on CTGF/CN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C gene, *Hum. Mol. Genet.* 25 (2016) 2220–2233.
- [11] C. Le Dour, C. Macquart, F. Sera, S. Homma, G. Bonne, et al., Decreased WNT/ $\beta$ -catenin signalling contributes to the pathogenesis of dilated cardiomyopathy caused by mutations in the lamin A/C gene, *Hum. Mol. Genet.* 26 (2017) 333–343.
- [12] A.R. Marks, Calcium cycling proteins and heart failure: mechanisms and therapeutics, *J. Clin. Invest.* 123 (2013) 46–52.
- [13] T. Arimura, A. Helbling-Leclerc, C. Massart, S. Varnous, F. Niel, et al., Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies, *Hum. Mol. Genet.* 14 (2005) 155–169.
- [14] G. Bonne, E. Mercuri, A. Muchir, A. Urtizberea, H.M. Bécane, et al., Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene, *Ann. Neurol.* 48 (2000) 170–180.
- [15] W. Xie, A. Chojnowski, T. Boudier, J.S. Lim, S. Ahmed, et al., A-type lamins form distinct filamentous networks with differential nuclear pore complex associations, *Curr. Biol.* 26 (2016) 2651–2658.
- [16] M. Periasamy, A. Kalyanasundaram, SERCA pump isoforms: their role in calcium transport and disease, *Muscle Nerve* 35 (2007) 430–442.
- [17] M. Periasamy, P. Bhupathy, G.J. Babu, Regulation of sarcoplasmic reticulum Ca<sup>2+</sup> ATPase pump expression and its relevance to cardiac muscle physiology and pathology, *Cardiovasc. Res.* 77 (2008) 265–273.
- [18] A.V. Zima, E. Bovo, S.R. Mazurek, J.A. Rochira, D. Terentyev, Ca handling during excitation-contraction coupling in heart failure, *Pflügers Archiv* 466 (2014) 1129–1137.
- [19] D. Peana, T.L. Domeier, Cardiomyocyte Ca<sup>2+</sup> homeostasis as a therapeutic target in heart failure with reduced and preserved ejection fraction, *Curr. Opin. Pharmacol.* 33 (2017) 17–26.
- [20] G.J. Babu, P. Bhupathy, C.A. Carnes, G.E. Billman, M. Periasamy, Differential expression of sarcolipin protein during muscle development and cardiac pathophysiology, *J. Mol. Cell. Cardiol.* 43 (2007) 215–222.
- [21] G.J. Babu, Z. Zheng, P. Natarajan, D. Wheeler, P.M. Janssen, et al., Overexpression of sarcolipin decreases myocyte contractility and calcium transient, *Cardiovasc. Res.* 65 (2005) 177–186.
- [22] M. Asahi, K. Kurzydowski, M. Tada, D.H. MacLennan, Sarcolipin inhibits polymerization of phospholamban to induce superinhibition of sarco(endo)plasmic reticulum Ca<sup>2+</sup>-ATPases (SERCA), *J. Biol. Chem.* 277 (2002) 26725–26728.
- [23] M. Asahi, Y. Sugita, K. Kurzydowski, S. De Leon, M. Tada, et al., Sarcolipin regulates sarco(endo)plasmic reticulum Ca<sup>2+</sup>-ATPase (SERCA) by binding to transmembrane helices alone or in association with phospholamban, *Proc. Natl. Acad. Sci. U.S.A.* 100 (2003) 5040–5043.
- [24] M. Asahi, K. Otsu, H. Nayakama, S. Hikoso, T. Takeda, et al., Cardiac-specific overexpression of sarcolipin inhibits sarco(endo)plasmic reticulum Ca<sup>2+</sup> ATPase (SERCA2a) activity and impairs function in mice, *Proc. Natl. Acad. Sci. U.S.A.* 101 (2004) 9199–9204.
- [25] M.E. Anderson, Connections count: excitation-contraction meets excitation-transcription coupling, *Circ. Res.* 86 (2000) 717–719.
- [26] J.D. Molkenkin, J.R. Lu, C.L. Antos, B. Markham, J. Richardson, et al., A calcineurin-dependent transcriptional pathway for cardiac hypertrophy, *Cell* 93 (1998) 215–228.
- [27] X. Wu, T. Zhang, J. Bossuyt, X. Li, T.A. McKinsey, et al., Local InsP3-dependent perinuclear Ca<sup>2+</sup> signaling in cardiac myocyte excitation-transcription coupling, *J. Clin. Invest.* 116 (2006) 675–682.
- [28] S.K. Maurya, N.C. Bal, D.H. Sopariwala, M. Pant, L.A. Rowland, et al., Sarcolipin is a key determinant of the basal metabolic rate, and its overexpression enhances energy expenditure and resistance against diet-induced obesity, *J. Biol. Chem.* 290 (2015) 10840–10849.
- [29] V.A. Fajardo, B.A. Rietze, P.J. Chambers, C. Bellissimo, E. Bombardier, et al., Effects of sarcolipin deletion on skeletal muscle adaptive responses to functional overload and unloading, *Am. J. Physiol. Cell Physiol.* 313 (2017) C1154–C1161.
- [30] V.A. Fajardo, P.J. Chambers, E.S. Juracic, B.A. Rietze, D. Gamu, et al., Sarcolipin deletion in mdx mice impairs calcineurin signalling and worsens dystrophic pathology, *Hum. Mol. Genet.* 27 (2018) 4094–4102.

- [31] J.A. Towbin, J.F. Hejtmančík, P. Brink, B. Gelb, X.M. Zhu, et al., X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus, *Circulation* 87 (1993) 1854–1865.
- [32] A. Voit, V. Patel, R. Pachon, V. Shah, M. Bakhutma, et al., Reducing sarcolipin expression mitigates Duchenne muscular dystrophy and associated cardiomyopathy in mice, *Nat. Commun.* 8 (2017) 1068.
- [33] J. Tanihata, T. Nagata, N. Ito, T. Saito, A. Nakamura, et al., Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition, *Biochem. Biophys. Res. Commun.* 505 (2018) 51–59.
- [34] N. Vignier, M. Chatzifrangkeskou, B. Morales Rodriguez, M. Mericskay, N. Mougnot, et al., Rescue of biosynthesis of nicotinamide adenine dinucleotide (NAD<sup>+</sup>) protects the heart in cardiomyopathy caused by lamin A/C gene mutation, *Hum. Mol. Genet.* 27 (2018) 3870–3880.
- [35] M. Chatzifrangkeskou, D. Yadin, T. Marais, S. Chardonnet, M. Cohen-Tannoudji, et al., Cofilin-1 phosphorylation catalyzed by ERK1/2 alters cardiac actin dynamics in dilated cardiomyopathy caused by lamin A/C gene mutation, *Hum. Mol. Genet.* 27 (2018) 3060–3078.
- [36] T. Arimura, R. Sato, N. Machida, H. Bando, D.-Y. Zhan, et al., Improvement of left ventricular dysfunction and of survival prognosis of dilated cardiomyopathy by administration of calcium sensitizer SCH00013 in a mouse model, *J. Am. Coll. Cardiol.* 55 (2010) 1503–1505.
- [37] H.M. Nef, H. Möllmann, C. Troidl, S. Kostin, S. Voss, et al., Abnormalities in intracellular Ca<sup>2+</sup> regulation contribute to the pathomechanism of Tako-Tsubo cardiomyopathy, *Eur. Heart J.* 30 (2009) 2155–2164.
- [38] J. Zheng, D.M. Yancey, M.I. Ahmed, C.-C. Wei, P.C. Powell, et al., Increased sarcolipin expression and adrenergic drive in humans with preserved left ventricular ejection fraction and chronic isolated mitral regurgitation, *Circ. Heart Fail.* 7 (2014) 194–202.
- [39] J.C. Harr, T.R. Luperchio, X. Wong, E. Cohen, S.J. Wheelan, K.L. Reddy, Directed targeting of chromatin of the nuclear lamina is mediated by chromatin state and A-type lamins, *J. Cell Biol.* 208 (2015) 33–52.
- [40] K.L. Reddy, J.M. Zullo, E. Bertolino, H. Singh, Transcriptional repression mediated by repositioning of genes to the nuclear lamina, *Nature* 452 (2008) 243–247.
- [41] V. Andres, J.M. Gonzalez, Role of A-type lamins in signaling, transcription, and chromatin organization, *J. Cell Biol.* 187 (2009) 945–957.
- [42] E. Lund, A.R. Oldenburg, E. Delbarre, C.T. Freberg, I. Duband-Goulet, et al., Lamin A/C-promoter interactions specify chromatin state-dependent transcription outcomes, *Genome Res.* 23 (2013) 1580–1589.
- [43] J. Perovanovic, S. Dell'Orso, V.F. Gnochì, J.K. Jaiswal, V. Sartorelli, et al., Laminopathies disrupt epigenomic developmental programs and cell fate, *Sci. Transl. Med.* 8 (2016) 335ra38.
- [44] N. Salvarani, S. Crasto, M. Miragoli, A. Bertero, M. Paulis, et al., The K219T-Lamin mutation induces conduction defects through epigenetic inhibition of SCN5A in human cardiac laminopathy, *Nat. Commun.* 10 (2019) 2267.
- [45] G. Ruiz-Hurtado, L. Li, M. Fernández-Velasco, A. Rueda, F. Lefebvre, et al., Reconciling depressed Ca<sup>2+</sup> sparks occurrence with enhanced RyR2 activity in failing mice cardiomyocytes, *J. Gen. Physiol.* 146 (2015) 295–306.